Having trouble accessing articles? Reset your cache.

Victoza liraglutide: Additional Phase III data

Additional data from an open-label, international Phase III trial in 665 patients inadequately controlled with metformin showed that 1.8 mg once-daily subcutaneous

Read the full 225 word article

User Sign In

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE